Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Xencor, Inc.
Atavistik Bio, Inc
Compass Therapeutics
Eli Lilly and Company
Whitehawk Therapeutics, Inc.
NiKang Therapeutics, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
AstraZeneca
Alterome Therapeutics, Inc.
Boehringer Ingelheim
Eli Lilly and Company
BeOne Medicines
Whitehawk Therapeutics, Inc.
Eli Lilly and Company
University of Miami
Accent Therapeutics
Seagen Inc.
AbbVie
Myeloid Therapeutics
Tizona Therapeutics, Inc
SEED Therapeutics, Inc.
Dana-Farber Cancer Institute
TORL Biotherapeutics, LLC
Normunity AccelCo, Inc.
BioNTech SE
NiKang Therapeutics, Inc.
IDEAYA Biosciences
MacroGenics
Mayo Clinic
Cogent Biosciences, Inc.
UNC Lineberger Comprehensive Cancer Center
SystImmune Inc.
Pheon Therapeutics
Solve Therapeutics
MOMA Therapeutics
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Eli Lilly and Company
Shanghai Best-Link Bioscience, LLC
Seagen Inc.
Fusion Pharmaceuticals Inc.
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Risen (Suzhou) Pharma Tech Co., Ltd.
GlaxoSmithKline